Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Anavex Life Sciences Corp. (AVXL) had Stock-Based Compensation of $11.55M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-9.83M |
|
-- |
|
-- |
|
$10.84M |
|
$-10.84M |
|
$1.02M |
|
$-9.83M |
|
$-9.83M |
|
$-9.83M |
|
$-9.83M |
|
$-9.83M |
|
$-9.83M |
|
$-10.84M |
|
$-10.84M |
|
85.29M |
|
85.29M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$103.81M |
|
-- |
|
-- |
|
$103.81M |
|
$8.95M |
|
-- |
|
-- |
|
$8.95M |
|
$94.87M |
|
$94.87M |
|
$94.87M |
|
86.67M |
|
| Cash Flow Statement Financials | |
$-39.04M |
|
-- |
|
$9.43M |
|
$132.19M |
|
$102.58M |
|
$-29.61M |
|
|
Stock-Based Compensation |
$11.55M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.36% |
|
-10.36% |
|
-9.47% |
|
-10.36% |
|
$1.09 |
|
$-0.46 |
|
$-0.46 |
|